Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Slides:

Advertisements

Similar presentations

Nat. Rev. Nephrol. doi: /nrneph

Advertisements

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 4 Expression of coagulation protease receptors in renal cells

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Role of the kidney in glucose homeostasis

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 2 Expression of complement activation products in renal samples

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The burden of chronic kidney disease (CKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Milestones in paediatric acute kidney injury (AKI) research

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Hammoud et al. Am J Nephrol 2016;44: (DOI: / )

Figure 2 Roles of mTOR complexes in the kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Schematic of an analysis of a new biopsy

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Figure 4 The molecular configuration of the CD20 molecule

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Determinants of renal contrast medium enrichment

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Serum phosphate level is associated with

Figure 1 Identification of anti-HLA antibodies

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Figure 1 The relationship between health fitness and pathogen load

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Preventive strategies for CSA-AKI

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target? Hatem Amer, Matthew D. Griffin Kidney International

Figure 4 Intracellular distribution and

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

primary Sjögren syndrome

Nat. Rev. Nephrol. doi: /nrneph

Overview of the cellular and molecular basis of kidney fibrosis

Quiz Page August 2013 American Journal of Kidney Diseases

The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Richard E. Gilbert, Mark E. Cooper Kidney.

Algorithm for management of drug-induced acute interstitial nephritis

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen transcripts and the progression of tubular atrophy and interstitial fibrosis (TA/IF) Figure 4 | The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen transcripts and the progression of tubular atrophy and interstitial fibrosis (TA/IF). Data represent average molecular scores from 282 biopsy samples obtained within the first year post-transplantation. The left y-axis represents the average molecular scores of pathogenesis based transcript sets, and the right y-axis represents average histologic ci-scores (indicative of TA/IF). Modified with permission from the American Society for Clinical Investigation © Venner, J.M. et al. JCI Insight 1, e85323 (2016). Modified with permission from the American Society for Clinical Investigation © Venner, J.M. et al. JCI Insight 1, e85323 (2016). Halloran, P. F. et al. (2016) Molecular assessment of disease states in kidney transplant biopsy samples Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.85